Hospital quality indicator may not be linked to patient survival after colon cancer surgeryNovember 14, 2007Examining a specific number of lymph nodes after colon cancer surgery, a measurement that has been recommended as a quality indicator for hospitals, is not associated with length of patient survival, according to a study in the November 14 issue of JAMA. Several studies have suggested improved survival among patients in whom a higher number of nodes are examined after colectomy for colon cancer (part or all of the colon is removed). Several organizations recently endorsed a 12-node minimum as a standard for hospital-based performance, according to background information in the article. Large private payers have already begun incorporating this measure into their pay-for-performance programs. Whether such efforts will improve outcomes for patients with colon cancer remains unclear, as is whether node counts are useful as an indicator of hospital quality. Sandra L. Wong, M.D., M.S., of the University of Michigan, Ann Arbor, and colleagues, using data from the national Surveillance Epidemiology and End Results (SEER)-Medicare linked database (1995-2005), assessed whether hospitals' lymph node examination rates were associated with cancer staging, use of adjuvant (supplemental) chemotherapy (indicated for patients with node-positive disease), and 5-year survival. The study included 30,625 patients undergoing colectomy for nonmetastatic colon cancer. Hospitals were ranked according to the proportion of their patients in whom 12 or more lymph nodes were examined and then were sorted into four groups. Late survival rates were assessed for each hospital group, adjusting for potentially confounding patient and clinician characteristics. Hospitals with the highest proportions of patients with 12 or more lymph nodes examined tended to treat lower-risk patients and had substantially higher procedure volumes. After adjusting for these and other factors, there remained no statistically significant relationship between hospital lymph node examination rates and survival after surgery. Although the four hospital groups varied widely in the number of lymph nodes examined, they were equally likely to find node-positive tumors. There were no clinically important differences in the use of adjuvant chemotherapy, either overall (unadjusted rates of 26 percent for the highest hospital quartile vs. 25 percent for the lowest hospital quartile) or within cancer stage subgroups. "Our study raises questions about the importance of examining a large number of lymph nodes in patients with colon cancer," the authors write. Regarding the finding of no evidence of higher 5-year survival at hospitals with higher lymph node examination rates: "Our analyses also suggest a simple explanation for these null findings. Regardless of how many lymph nodes hospitals examined, they tended to find the same number of node-positive ones. As a result, higher hospital lymph node examination rates did not result in greater detection of patients with node-positive tumors or higher rates of adjuvant chemotherapy." "Using lymph node counts as a hospital quality indicator is gaining momentum from stakeholders in the health care community," the researchers write. "The number of lymph nodes hospitals examine following colectomy for colon cancer is not associated with staging, use of adjuvant chemotherapy, or patient survival. Efforts by payers and professional organizations to increase node examination rates may have limited value as a public health intervention." JAMA and Archives Journals |
|||||||||||||||||||||
| Related Lymph Nodes Current Events and Lymph Nodes News Articles Hundreds of genes distinguish patients likely to survive advanced melanoma Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Cell study explains why younger people more at risk of vCJD Specific cells within the immune system could help explain why younger people are more susceptible to variant CJD, scientists believe. Genes signal late-stage laryngeal cancer, poorer outcome Researchers at Henry Ford Hospital have identified tumor-suppressing genes that may provide a more accurate diagnosis of disease stage and survival for laryngeal cancer patients than current standards. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness. Study finds 231 new genes associated with head and neck cancer A Henry Ford Hospital study has identified 231 new genes associated with head and neck cancer, one of the most deadly cancers responsible for 2.1 percent of all cancer deaths in the United States. Prostate cancer gives a new outlook on life Men who have prostate cancer often feel quite healthy, but the diagnosis still gives them a whole new outlook on life. Once they have learned to live with their cancer, they choose to focus on valuable relationships and appreciate the little things in life, shows a dissertation thesis from the Sahlgrenska Academy. Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine Regenerative medicine researchers at the University of Pittsburgh received two grants totaling more than $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from existing tissues and organs. Ultrasound can predict tumor burden and survival in melanoma patients Researchers have shown for the first time that patterns of ultrasound signals can be used to identify whether or not cancer has started to spread in melanoma patients, and to what extent. The discovery enables doctors to decide on how much surgery, if any, is required and to predict the patient's probable survival. Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop. More Lymph Nodes Current Events and Lymph Nodes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||